Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

Error: Response status code does not indicate success: 503 (Service Unavailable).

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) has earned a consensus recommendation of "Buy" from the eight ratings firms that are currently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $32.6667.

A number of equities research analysts recently commented on the company. Wedbush assumed coverage on Maze Therapeutics in a research note on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price objective for the company. Guggenheim boosted their target price on Maze Therapeutics from $19.00 to $34.00 and gave the company a "buy" rating in a research note on Monday, September 15th. Wall Street Zen raised Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Maze Therapeutics in a research note on Thursday, September 18th. Finally, BTIG Research boosted their target price on Maze Therapeutics from $30.00 to $37.00 and gave the company a "buy" rating in a research note on Friday, September 12th.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the business's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. TRV GP IV LLC bought a new stake in shares of Maze Therapeutics in the first quarter valued at about $66,874,000. Frazier Life Sciences Management L.P. lifted its holdings in shares of Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock valued at $56,040,000 after purchasing an additional 438,274 shares in the last quarter. ARCH Venture Management LLC bought a new stake in shares of Maze Therapeutics in the first quarter valued at about $45,362,000. Matrix Capital Management Company LP bought a new stake in Maze Therapeutics during the first quarter worth about $27,373,000. Finally, Alphabet Inc. bought a new stake in Maze Therapeutics during the first quarter worth about $26,561,000.

Maze Therapeutics Stock Up 1.4%

Shares of Maze Therapeutics stock traded up $0.34 during trading on Friday, reaching $24.01. 169,986 shares of the company were exchanged, compared to its average volume of 281,903. Maze Therapeutics has a twelve month low of $6.71 and a twelve month high of $25.50. The business has a 50-day moving average price of $16.31 and a 200-day moving average price of $12.76.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.